James Investment Research’s ARK Genomic Revolution ETF ARKG Stock Holding History

James Investment Research’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,791	Closed	-$232K	–	501
2021 Q4	$232K	Sell	3,791 -2,450	-39%	-$169K	0.02%	276
2021 Q3	$466K	Sell	6,241 -29,019	-82%	-$2.43M	0.04%	201
2021 Q2	$3.26M	Sell	35,260 -2,039	-5%	-$173K	0.28%	96
2021 Q1	$3.31M	Sell	37,299 -7,748	-17%	-$769K	0.3%	96
2020 Q4	$4.2M	Buy	45,047 +2,469	+6%	+$197K	0.38%	83
2020 Q3	$2.71M	Buy	42,578 +6,472	+18%	+$379K	0.25%	104
2020 Q2	$1.88M	Buy	+36,106	New	+$1.55M	0.18%	116

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

James Investment Research's ARKG Position: Q1 2022 in Review

James Investment Research sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 3,791 shares — an estimated $232K sold.

James Investment Research first reported a position in ARKG in Q2 2020 and held it in 7 quarters. The position peaked at $4.2M in Q4 2020. 388 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

James Investment Research reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
James Investment Research sold 3,791 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $232K.
James Investment Research first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 7 quarters.
James Investment Research's ARK Genomic Revolution ETF position peaked at $4.2M in Q4 2020.
388 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on James Investment Research's 13F filing for Q1 2022, filed 22 Apr 2022.